Literature DB >> 772425

Renin profiling in hypertension and its use in treatment with propranolol and chlorthalidone.

J W Woods, A W Pittman, C C Pulliam, E E Werk, W Waider, C A Allen.   

Abstract

We compared methods of classifying hypertension according to plasma renin activity in 54 patients with essential hypertension and examined the validity of using these classifications to choose between two hypotensive drugs. A prospective, double-blind crossover study was used. Normal values for plasma renin activity were established from 111 control subjects. Plasma renin activity was related to race and inversely to age in hypertensive patients (P less than 0.05) but not in normal subjects. Three methods of classification correlated well but did not identify exactly the same renin-suppressed patients. Chlorthalidone produced a greater reduction in blood pressure and restored blood pressure to normal in a larger percentage of patients in both low-renin (59 per cent) and normal-renin (32 per cent) subgroups than propranolol (12 and 16 per cent). Renin determinations are of limited benefit in the choice of therapy for most patients with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 772425     DOI: 10.1056/NEJM197605202942101

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  17 in total

1.  Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.

Authors:  Stephen T Turner; Gary L Schwartz; Arlene B Chapman; Amber L Beitelshees; John G Gums; Rhonda M Cooper-DeHoff; Eric Boerwinkle; Julie A Johnson; Kent R Bailey
Journal:  Am J Hypertens       Date:  2010-08-19       Impact factor: 2.689

2.  Hypertension symposium: newer topics on normal and abnormal blood pressure regulatory mechanisms.

Authors:  M L Tuck; M S Golub; P Eggena; J R Sowers; M Maxwell
Journal:  West J Med       Date:  1983-08

3.  Hypotensive effects of sodium volume depletion and 1-sar-8-ala-angiotensin II in relation to plasma renin in hypertensive patients.

Authors:  R Fagard; A Amery; P Lijnen; T Reybrouck
Journal:  Eur J Clin Pharmacol       Date:  1977-08-17       Impact factor: 2.953

Review 4.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

5.  Propranolol versus labetalol: interesting differences in efficacy.

Authors:  W Flamenbaum
Journal:  J Natl Med Assoc       Date:  1985-05       Impact factor: 1.798

6.  The response to the angiotensin antagonist saralasin in predicting therapeutic outcome in hypertension treated with frusemide.

Authors:  A Burke; C R George; E P MacCarthy; G S Stokes
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

Review 7.  Antihypertensive pharmacology.

Authors:  J G Gerber; C R Freed; A S Nies
Journal:  West J Med       Date:  1980-05

8.  A study of the effects of atenolol and propranolol on renal function in patients with essential hypertension.

Authors:  R Wilkinson; I M Stevens; M Pickering; V Robson; T Hawkins; D N Kerr; J D Harry
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

Review 9.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

10.  Acebutolol in hypertension--double-blind trial against placebo.

Authors:  M A Martin; C A Phillips; A J Smith
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.